Severe cytomegalovirus gastritis and hypogammaglobulinemia in a patient treated with pembrolizumab.

Eur J Gastroenterol HepatolJun 3, 2026 (epub)
Case ReportGastroenterologyOncology (Medical)

Federico Sottotetti, Giovanni Arpa, Lucrezia Spina et al.

✦ AI-curated · Sources linked

Case in brief

A 66-year-old man with stage IVB oesophageal carcinoma, treated with pembrolizumab, presented with gastric erosions and ulcers. Biopsies revealed lymphoplasmacytic and neutrophilic infiltrates, indicating immune checkpoint inhibitor-induced gastritis. Following transient relief with high-dose steroids, cytomegalovirus (CMV) DNA was detected in gastric biopsies. After steroid withdrawal and treatment with intravenous ganciclovir, the patient showed partial improvement, but developed haemorrhagic gastritis due to hypogammaglobulinemia, which resolved rapidly with intravenous immunoglobulins.

Diagnostic / clinical pearl

Clinicians should consider tissue-based CMV testing in patients with severe gastritis, especially those on immunotherapy, and be cautious with steroid use.

Why it matters

This case highlights the potential for severe immunodeficiency in patients receiving immune checkpoint inhibitors, necessitating careful monitoring and management.

Source

PubMed · PMID 42467928

Published in Eur J Gastroenterol Hepatol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.